HLB Presents Riboceranib Excellence at AACR
Elevate COO Dr. Jang Sung-hoon Leads Research
Riboceranib Demonstrates High Selectivity and Low Side Effects
HLB announced on the 20th that it will consecutively present research results on 'Riboceranib,' a new drug application (NDA) under preparation for submission to the U.S. Food and Drug Administration (FDA), at globally prestigious academic conferences.
On the 22nd, the Clinical Pharmacology Society (ASCPT) will disclose the pharmacokinetic interaction results of Riboceranib and other drugs. From the 14th to the 19th of next month, at the American Association for Cancer Research (AACR) held in Orlando, Florida, USA, research results on the "Comparative biochemical activity analysis of Riboceranib, which selectively inhibits VEGFR-2 more than other TKI agents that inhibit the neovascularization receptor (VEGFR-2)" will also be presented.
The paper was led by key bio experts from Eleva. Dr. Seonghoon Jang, former FDA Chief Operating Officer (COO), participated as the first author, with Bill Strickland and Lynda Finis as co-authors. Dr. Jang will reveal various research results confirming Riboceranib’s high selectivity for VEGFR-2 and low side effects compared to multiple anti-neovascularization TKI agents.
The paper was selected as a Late-Breaking abstract. Detailed information remains confidential. The full abstract will be available on the 14th of next month.
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- Trump Pressures Taiwan to Relocate Semiconductor Industry to U.S., Says "Taiwan Took Away America's Semiconductor Industry"
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
Previously, HLB completed a Phase 3 combination clinical trial of Riboceranib plus Camrelizumab involving 543 patients across 12 countries including the U.S., Europe, and Asia, aiming to develop a first-line treatment for liver cancer. The research results were presented at the European Society for Medical Oncology (ESMO 2022). The clinical results showed a median overall survival (mOS) of 22.1 months, demonstrating the highest efficacy to date. The primary efficacy endpoint was met. HLB is accelerating final preparations by forming a joint team with Hansoh Pharmaceutical, which holds Camrelizumab, targeting NDA submission in May.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
